Jebinta Cusub
Shirkadda Israa’iil ee Teknoolojiyada Caqliga Fudud (AI) ee CytoReason ayaa ballaarisay iskaashigeeda daahfurka daawooyinka oo ay la gashay Sanofi oo ka socota Faransiiska
Shirkadda Israa'iili ee tignoolajiyada maskaxda (AI) ee CytoReason ayaa ballaarisay iskaashigeedii horumarinta dawooyinka ee Sanofi, iyadoo saxiixday heshiis cusub oo soconaya sanado badan, qiimihiisuna gaarayo ilaa $16 milyan, taasoo calaamad u ah heshiiskeedii shanaad ee ganacsi.
Yeruusaalem, 11 Janaayo, 2026 (TPS-IL) — shirkadda Israa’iil ee daawooyinka ka soo saarta iyada oo isticmaalaysa AI ee CytoReason ayaa ballaarisay iskaashigeedii la lahaa shirkadda weyn ee daawooyinka Faransiiska ee Sanofi markii saddexaad, iyada oo hoos imaanaysa heshiis cusub oo soconaya sanado badan oo qiimihiisu yahay ilaa $16 milyan. Heshiiskan oo laga shaaciyey Tel Abiib, ayaa noqonaya heshiiskii shanaad ee ganacsi ee CytoReason ee 2025, waxana uu sii xoojinayaa saamaynteeda sii kordheysa ee ka dhaxaysa hoggaamiyeyaasha daawooyinka adduunka.
Tignoolajiyada CytoReason waxa ay isticmaashaa qaababka xisaabinta ee horumarsan ee cudurrada si ay uga caawiso kooxaha R&D inay helaan macluumaad la isticmaali karo oo ka yimaada xogta unugyada iyo tan caafimaad, taas oo dardar-gelisa go’aan-qaadashada barnaamijyada horumarinta daawooyinka. shirkadda, oo ay maalgelinayaan maalgashadayaasha Maraykanka oo ay ku jiraan NVIDIA, Thermo Fisher Scientific, iyo Pfizer, waxa ay la shaqaysaa qiyaastii kala bar shirkadaha daawooyinka ee ugu sarreeya 20ka adduunka.
